Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
115 hedge funds and large institutions have $956M invested in Acceleron Pharma in 2015 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 31 reducing their positions, and 15 closing their positions.
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
29% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 31
5% more funds holding
Funds holding: 110 → 115 (+5)
1% less capital invested
Capital invested by funds: $966M → $956M (-$9.91M)
14% less call options, than puts
Call options by funds: $5.99M | Put options by funds: $6.99M
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$19M |
| 2 |
PC
PointState Capital
New York
|
+$18.9M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$6.51M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$5.36M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$4.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$22.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.43M |
| 3 |
QF
QVT Financial
New York
|
-$7.98M |
| 4 |
PVMCI
Polaris Venture Management Co IV
Boston,
Massachusetts
|
-$7.31M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.51M |
XLRN Hedge Fund Activity: Q1 2015 in Review
115 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2015, worth a combined $956M — down 1% from $966M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new XLRN positions and 15 closed out — a net gain of 6 holders — while 40 added to existing stakes and 31 trimmed.
The largest buyer was Oak Ridge Investments, adding an estimated $19M. The largest seller was Adage Capital Partners, cutting an estimated $22.8M.
- 115 institutional investors held Acceleron Pharma (XLRN) as of Q1 2015, up from 110 in Q4 2014.
- Funds reported $956M of Acceleron Pharma stock for Q1 2015, down 1% quarter-over-quarter.
- 21 funds opened new Acceleron Pharma positions in Q1 2015 and 15 closed out, a net change of +6 holders.
- The largest Acceleron Pharma buyer in Q1 2015 was Oak Ridge Investments, an estimated $19M added.
- The largest Acceleron Pharma seller in Q1 2015 was Adage Capital Partners, an estimated $22.8M sold.
Based on aggregated 13F filings for Q1 2015.